Search PubMed⌕ Search

Biomedical subjects

J Waxman

Publications and source records attributed to J Waxman.

At least 73 records · Page 4Linked to original sources

Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide.

The prognosis of patients with metastatic adrenal cortical carcinoma is poor, and their disabling symptoms are usually unresponsive to conventional therapy. A patient with Cushing's syndrome secondary to a secretory adrenal cortical carcinoma was treated with octreotide, endocrine therapy and chemotherapy having failed. Treatment led to a dramatic relief of her symptoms with a fall in corticosteroid secretion. Somatostatin analogue therapy for this tumour should be encouraged in view of the lack of alternative palliative treatment.

Adrenal Cortex Neoplasms↗

Tumour markers.

Tumour markers are now used in the diagnosis, anatomical localization, staging, monitoring and definition of prognosis of a wide range of malignancies. The last decade has seen an expansion of our definition of these markers to include oncogenes and oncogene products, and provided us with new possibilities of developing more specific tests to help in the management of cancer.

Antigens, Tumor-Associated, Carbohydrate↗

Multiple primary cancers in association with prostate cancer.

Patients with prostate cancer are at a significant risk of either having a preceding tumour or developing a second malignancy. The precise mechanism by which second cancers develop is not clear but may be the result of exposure to a shared mutagen, abnormalities in oncogene activation or the aberrant expression of tumour suppressor genes. In the recent past, case reports and tumour registry studies on the risk of second cancer development have been important and have alerted the clinician that careful surveillance in this group of patients is required. More prospective hospital based studies are required to delineate the true risk of second malignancies in association with prostate cancer.

Age Factors↗

Combined choriocarcinoma and yolk sac tumor arising in Barrett's esophagus.

A patient with primary adenocarcinoma with yolk sac and trophoblastic differentiation occurring in Barrett's esophagus is reported. Yolk sac differentiation at this site has not been described previously. The diagnosis of germ cell differentiation initially was suggested by the finding of elevated serum tumor marker levels. The patient experienced disease remission after cytotoxic chemotherapy. Germ cell differentiation may be difficult to identify in small biopsy samples, which may not be representative of the tumor as a whole. The finding of germ cell differentiation defines therapy and predicates for a relatively good prognosis, which is contrast to adenocarcinoma. Because of the significance of germ cell differentiation in the selection of appropriate therapy, immunostaining for germ cell tumor markers is suggested in all patients with adenocarcinoma who are younger than 50 years.

Adenocarcinoma↗

Palliation of malignant intestinal obstruction using octreotide.

Vomiting due to malignant intestinal obstruction is an unpleasant terminal event in many cancer patients, which responds poorly to conventional therapies. Somatostatin and its long-acting analogues reduce intestinal secretion. For this reason, octreotide was used in a phase I/II study of patients with intractable vomiting secondary to intestinal obstruction due to malignant disease. Vomiting was controlled or the volume of nasogastric aspirate was markedly reduced in 18 of 24 (75%) patients receiving a subcutaneous infusion of octreotide (median initial dose 300, range 100-600 micrograms/day) for a median of 9.4 (range 1-38) days. A further 2 patients had partial relief of their symptoms. Octreotide is an effective treatment of nausea and vomiting due to malignant bowel obstruction.

Adult↗

Serum metalloproteinases and their inhibitors: markers for malignant potential.

Death from cancer results from the development of metastases or local progression of tumour. Metastasis and local progression may result from the inappropriate activity of metalloproteinases released by tumour cells or of their regulatory peptides. We have developed quantitative assays for interstitial collagenase, stromelysin 1 and tissue inhibitors of metalloproteinase (TIMP) 1 and 2, which have allowed the study of serum levels of these proteins. Sera from 40 patients with prostatic cancer, stored prior to and after 6 and 12 months' treatment with a gonadotrophin-releasing hormone agonist and an anti-androgen were analysed. Levels were compared with two control groups, comprising 21 patients with active rheumatoid arthritis and 56 age-matched hospital attenders without arthritis or cancer. Contrasting levels have been found in patients with prostatic cancer as compared with hospital controls without cancer and patients with rheumatoid arthritis. Patients with prostatic cancer had higher levels of TIMP-1 and collagenase (P = 0.0001) and lower levels of TIMP-2 (P = 0.003) than controls. Patients with metastatic cancer had significantly higher levels of collagenase than those without metastases (P = 0.02). Patients with rheumatoid arthritis had significantly higher levels of stromelysin than either controls (P = 0.002) or patients with cancer (P = 0.008). Serum tissue inhibitor of metalloproteinase 1 in combination with collagenase levels was as sensitive as prostate-specific antigen as a marker of metastatic disease. These findings provide a basis for the investigation of the role of metalloproteinases and their inhibitors in other malignancies.

Arthritis, Rheumatoid↗

Platinum-based chemotherapy for bladder cancer.

The majority of patients with advanced urothelial cancer are not cured by surgery or radiotherapy. This report reviews the results of radiation and surgery in the treatment of this malignancy and puts advances that have been made with chemotherapy into this context.

Antineoplastic Combined Chemotherapy Protocols↗

Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.

We have used quantitative zymography to measure levels of the type IV collagenases matrix metalloproteinase (MMP)-9 and MMP-2 in 42 biopsies of transitional cell carcinoma and in 7 biopsies of normal bladder. Mean levels of MMP-9 were significantly higher in tumor compared with normal samples (P = 0.08). Levels of MMP-9 and active MMP-2 increased with tumor grade (test for trend, P = 0.002 and P = 0.05, respectively). Levels of MMP-9 and activated MMP-2 were also higher in invasive tumors than in superficial ones (P = 0.001 and P = 0.008, respectively). In situ hybridization studies showed that the mRNAs for both MMP-2 and MMP-9 were located chiefly in the stroma rather than epithelial tumor cells and were concentrated at the interface between the two tissues.

Carcinoma, Transitional Cell↗

Chronic liver disease due to hepatitis C.

The low concentration of hepatitis C virus in the blood of infected patients has made it difficult to detect. Infected patients can now be identified by using more sensitive immunoassays and amplification of viral RNA by the polymerase chain reaction. Nevertheless, the virus remains difficult to eliminate. We present the case of a woman with a history of autoimmune haemolytic anaemia, thrombocytopenia, and common variable immunodeficiency who developed chronic hepatitis.

Adult↗

Carboplatin-based chemotherapy for bladder cancer.

Urothelial cancer is common and the prognosis of patients with locally advanced tumors treated with conventional treatment is poor. In this trial we examined responses among 72 urothelial cancer patients referred for treatment with MVMJ (methotrexate/vinblastine/mitoxantrone/carboplatin) chemotherapy. Sixty-four evaluable patients, 37 with locally advanced and 27 with metastatic urothelial cancer, were treated. Twenty-nine (45%) of the 64 patients had a complete or partial response, 15 (23%) had stable disease, and 13 (20%) had disease progression. The median survival of the responding patients has not been reached (range, 114 to 1184+ days). Twelve patients (32%) with locally advanced disease had a complete response to treatment; their median survival has not been reached and ranges up to 1131+ days. Five patients (18%) with metastatic cancer had a complete response to treatment and their median survival was 497 days (range, 184 to 637+). There were seven deaths within the first treatment month.

Adult↗

Cogan's syndrome manifesting as sudden bilateral deafness: diagnosis and management.

Cogan's syndrome is an uncommon entity of nonsyphilitic interstitial keratitis with vestibulo-auditory disturbances. Although it is unusual, Cogan's syndrome should be considered in the differential diagnosis of patients with sudden hearing loss, even when they lack ophthalmologic symptoms. Systemic manifestations are not uncommon and, along with serologic and hematologic abnormalities, may help in making the diagnosis, which requires a high index of suspicion. Treatment with steroids has largely been based on symptoms. We suggest using the C-reactive protein level as a monitor of subclinical disease activity; it is therefore beneficial in the adjustment of steroid therapy. We have described the case of a 41-year-old woman who sought treatment for an upper respiratory infection syndrome and severe vertigo. Evaluation included hematologic and serologic studies, lumbar puncture, and CT and MRI scans. Abnormal findings consisted of an elevated white blood cell count and an ESR of 112 mm/hr. Six days later, profound, bilateral sensorineural hearing loss developed suddenly. Intensive corticosteroid and vasodilator therapies were instituted, but there was no improvement in hearing levels. Ten days later eye pain and redness developed, and ophthalmologic evaluation revealed an interstitial keratitis consistent with Cogan's syndrome. Steroid eye drops and oral prednisone therapy promptly relieved the eye symptoms. Steroid tapering was associated with diffuse joint pain and swelling consistent with a systemic vasculitis. After rheumatologic consultation, steroid dosage was titrated to the CRP level and ESR, and vasculitic symptoms resolved. Hearing levels did not improve, and the patient had cochlear implantation. Thirteen cases of bilateral sudden deafness due to Cogan's syndrome have been reported previously. This is the first case in which there were no immediate eye symptoms.

Adult↗